Piper Jaffray Companies reissued their buy rating on shares of Rewalk Robotics (NASDAQ:RWLK) in a research report sent to investors on Sunday morning. Piper Jaffray Companies currently has a $3.00 price objective on the medical device company’s stock.
A number of other equities analysts have also weighed in on RWLK. Jefferies Group lowered their price target on shares of Rewalk Robotics from $8.00 to $5.00 and set a buy rating on the stock in a research report on Friday, November 3rd. Canaccord Genuity restated a buy rating and set a $3.00 price target on shares of Rewalk Robotics in a research report on Monday, November 6th. Zacks Investment Research upgraded shares of Rewalk Robotics from a hold rating to a buy rating and set a $1.50 price target on the stock in a research report on Thursday, November 9th. Finally, Oppenheimer set a $3.00 price target on shares of Rewalk Robotics and gave the stock a buy rating in a research report on Tuesday, December 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $2.83.
Shares of Rewalk Robotics (RWLK) opened at $1.10 on Friday. Rewalk Robotics has a 52-week low of $1.05 and a 52-week high of $3.20. The stock has a market cap of $31.82, a PE ratio of -0.69 and a beta of 0.79. The company has a debt-to-equity ratio of 7.46, a current ratio of 2.02 and a quick ratio of 1.65.
A hedge fund recently raised its stake in Rewalk Robotics stock. Advisor Group Inc. increased its holdings in shares of Rewalk Robotics Ltd (NASDAQ:RWLK) by 1,495.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 181,900 shares of the medical device company’s stock after acquiring an additional 170,500 shares during the quarter. Advisor Group Inc. owned about 0.82% of Rewalk Robotics worth $264,000 at the end of the most recent reporting period. 3.23% of the stock is owned by hedge funds and other institutional investors.
About Rewalk Robotics
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Receive News & Ratings for Rewalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rewalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.